EAF Soars 75% on Pricing Inflection; GMAB, KIDS, SLNH Lead EPS-Revision Rally
GrafTech International (EAF) surged 75.2% to $12.18 after guiding to a Q4 pricing increase and closing its highest-cost plant, following an EPS growth estimate of 35.0% for next year. Genmab (GMAB) rose 48.8% to $57.29 on a J.P. Morgan upgrade and positive Phase 3 cancer trial data, while OrthoPediatrics (KIDS) gained 39.8% to $30.80 after its third consecutive revenue guidance raise. Soluna Holdings (SLNH) and XTI Aerospace (XTIA) added 35.9% and 28.2%, respectively, on HPC joint-venture and drone revenue news.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| EAF | Industrials | 2026-10-20 | N/A | +75.2% |
| GMAB | Healthcare | 2026-10-19 | +2.4pp | +48.8% |
| KIDS | Healthcare | 2026-10-19 | +3.4pp | +39.8% |
| SLNH | Financial | 2026-10-22 | N/A | +35.9% |
| XTIA | Industrials | 2026-10-22 | N/A | +28.2% |
Why did EAF stock jump in October 2026?
EAF jumped 75.2% (from $6.95 to $12.18) after analysts set its forward EPS growth estimate at 35.0% on October 20, following a Q3 beat and a pricing inflection.
The graphite electrode maker reported an adjusted loss of $1.21 per share, 17.1% better than consensus, and revenue of $140.2 million that beat estimates by 10.7%. Management guided to a mid-single-digit sequential price increase in Q4 and announced the closure of its high-cost Monterrey plant, reinforcing the margin turnaround story. The stock's rally reflects growing confidence that realized pricing has bottomed and that cost cuts will drive meaningful EPS growth in 2027.
EAF EPS revision history → · Screener snapshot from 2026-10-20 →
FAQ: EAF
Why did EAF stock jump in October 2026?
EAF jumped 75.2% to $12.18 after its October 20 detection with a 35.0% next-year EPS growth estimate, fueled by a Q3 beat and Q4 pricing guidance.
Is EAF a buy after its 75% rally?
Analysts see further upside if GrafTech delivers its promised mid-single-digit price increase and cost savings from the Monterrey closure, but the balance sheet remains leveraged.
What is EAF's EPS growth estimate for next year?
The current EPS growth next year estimate for EAF is 35.0%, according to the latest analyst revisions.
Why did GMAB stock jump in October 2026?
GMAB surged 48.8% (from $38.50 to $57.29) after its next-year EPS growth estimate was revised upward to 48.8% from 46.3% on October 19, driven by positive cancer trial data.
J.P. Morgan upgraded the stock to overweight and doubled its price target to DKr3,500, citing petosemtamab's potential in head and neck cancer. On October 28, Genmab announced that petosemtamab reduced the risk of death by 50% in a Phase 3 trial, sending shares up 16% on the day. The combination of a major analyst upgrade, positive clinical results, and a rising EPS outlook has fueled the stock's strong rally.
GMAB EPS revision history → · Screener snapshot from 2026-10-19 →
FAQ: GMAB
Why did GMAB stock jump in October 2026?
GMAB rose 48.8% to $57.29 after its EPS growth estimate was revised up to 48.8% on October 19, followed by a J.P. Morgan upgrade and positive Phase 3 data for petosemtamab.
What caused Genmab's 16% surge on October 28?
Genmab announced that its drug petosemtamab reduced the risk of death by 50% in a head and neck cancer trial, meeting both primary endpoints.
What is GMAB's EPS growth estimate?
Genmab's next-year EPS growth estimate is 48.8%, up 2.4 percentage points from the prior estimate.
Why did KIDS stock jump in October 2026?
KIDS gained 39.8% (from $22.03 to $30.80) after its next-year EPS growth estimate was raised to 35.6% from 32.2% on October 19, following a strong Q3 report.
OrthoPediatrics reported record revenue of $72.7 million, up 19% year-over-year, and beat the consensus EPS loss by 8%. Management raised full-year revenue guidance for the third consecutive time to $270–273 million, implying 14–16% growth. The stock's rally reflects investor confidence in the company's accelerating top-line momentum and its path to profitability.
KIDS EPS revision history → · Screener snapshot from 2026-10-19 →
FAQ: KIDS
Why did KIDS stock jump in October 2026?
KIDS rose 39.8% to $30.80 after its EPS growth estimate was revised up to 35.6% on October 19, and the company reported 19% revenue growth with a guidance raise.
Is KIDS a buy after the rally?
The stock's momentum is supported by three consecutive guidance raises and improving revenue growth, but margin leverage remains a concern as EBITDA guidance was unchanged.
What is KIDS's EPS growth estimate?
OrthoPediatrics' next-year EPS growth estimate is 35.6%, up 3.4 percentage points from the previous estimate.
Why did SLNH stock jump in October 2026?
SLNH jumped 35.9% (from $0.53 to $0.72) after its next-year EPS growth estimate was set at 33.3% on October 22, following a joint venture with Applied Digital for an AI data center.
Soluna agreed to develop the 50 MW Dorothy 3 HPC campus, with Applied Digital owning 51% and providing financing. Rosenblatt reiterated its Buy rating but cut its price target to $2, implying significant upside from the current price. The stock's gain reflects growing interest in Soluna's pivot to high-performance computing infrastructure.
SLNH EPS revision history → · Screener snapshot from 2026-10-22 →
FAQ: SLNH
Why did SLNH stock jump in October 2026?
SLNH rose 35.9% to $0.72 after its EPS growth estimate was set at 33.3% on October 22, and it announced a joint venture with Applied Digital for a 50 MW AI data center.
Is SLNH a buy after the rally?
Rosenblatt maintains a Buy rating with a $2 price target, citing the company's HPC transition, though it notes the joint venture is less profitable than initially expected.
What is SLNH's EPS growth estimate?
Soluna Holdings' next-year EPS growth estimate is 33.3%, based on the latest analyst projections.
Why did XTIA stock jump in October 2026?
XTIA rose 28.2% (from $0.85 to $1.09) after its next-year EPS growth estimate was set at 74.6% on October 22, following preliminary Q3 revenue of $35.3 million.
The drone solutions provider reported a 9% sequential revenue increase and maintained its full-year revenue outlook of $125–130 million. The company also highlighted reductions in corporate overhead and lower cash burn. The stock's rally reflects optimism about XTI's growth trajectory despite near-term liquidity concerns.
XTIA EPS revision history → · Screener snapshot from 2026-10-22 →
FAQ: XTIA
Why did XTIA stock jump in October 2026?
XTIA rose 28.2% to $1.09 after its EPS growth estimate was set at 74.6% on October 22, and it reported preliminary Q3 revenue of $35.3 million, up 9% sequentially.
Is XTIA a buy after the rally?
The stock's high growth estimate and revenue momentum are attractive, but investors should weigh the company's near-term liquidity needs and low share price.
What is XTIA's EPS growth estimate?
XTI Aerospace's next-year EPS growth estimate is 74.6%, reflecting expectations for significant improvement.
Today's top performers highlight a market that continues to reward companies delivering tangible earnings revisions and strategic catalysts, from GrafTech's pricing turnaround to Genmab's clinical success. The strong gains in small-cap names like SLNH and XTIA also suggest speculative appetite remains robust for high-growth stories despite broader macro uncertainties.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →